Certain Dermatological Treatment Devices and Components Thereof; Notice of a Commission Determination Finding a Violation of Section 337 as to Four Asserted Patents; Issuance of a Limited Exclusion Order and Cease and Desist Orders; Remand of The Investigation as to One Asserted Patent; Extension of the Target Date

U.S. International Trade Commission.

Notice is hereby given that the U.S. International Trade Commission has found a violation of section 337 and has determined to issue: a limited exclusion order prohibiting the unlicensed importation of certain dermatological treatment devices and components thereof that infringe one or more of claims 1, 9, and 22 of U.S. Patent No. 9,480,836 (“the '836 patent”); claims 11 and 16 of U.S. Patent No. 9,320,536 (“the '536 patent”); claim 14 of U.S. Patent No. 9,775,774 (“the '774 patent”); and claims 5, 13, and 18 of U.S. Patent No. 10,869,812 (“the '812 patent”); cease and desist orders against Respondents EndyMed Medical Ltd. of Caesarea, Israel; EndyMed Medical, Ltd. of New York, New York; and EndyMed Medical, Inc. of Freehold, New Jersey (collectively, “EndyMed”); and set a bond in the amount of eighty-five percent (85%) of the entered value of the EndyMed Pure, and seventy percent (70%) of the entered value of the EndyMed Pro infringing products imported during the period of Presidential review. The investigation is terminated with respect to these four patents. The Commission has also determined to reverse the presiding administrative law judge's (“ALJ”) finding that asserted claims 4, 6, and 7 of U.S. Patent No. 11,406,444 (“the '444 patent”) are indefinite, remand the investigation to the ALJ with respect to that patent consistent with the concurrently issued Commission opinion and remand order, and extend the target date for completion of the investigation.